Dicot's toxicology program successfully completed

Dicot is developing a novel potency drug that aims to become the first choice of  treatment for erectile dysfunction and premature ejaculation. The company plans to start clinical studies with the drug candidate LIB-01 in mid-2023.

Today the company announces that the preclinical toxicology program required for clinical phase 1 with LIB-01 has been completed. LIB-01 has shown a good safety profile in the toxicity studies. In accordance with regulations, studies supporting both single dose and repeated dosing in the clinical trial have been conducted in two animal species. The studies have been performed according to Good Laboratory Practice.

Studies of a drug candidate's toxicity constitute a necessary and important part of the safety assessment before the start of clinical studies and are part of the documentation that must be assessed and approved by the authorities before start of clinical trials.

"The successful completion of the toxicology program is a great progress towards the start of our clinical studies and the fact that LIB-01 demonstrates a good safety profile in the program is of course very gratifying," comments Elin Trampe, CEO at Dicot.